Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biomet Redoubles Efforts To Revitalize Ailing Trauma and Spine Business

This article was originally published in The Gray Sheet

Executive Summary

Biomet says it is making significant progress in "stabilizing" its trauma and spine business, despite another underperforming quarter

You may also be interested in...



Biomet’s Struggling Spine Business Is Nearly Back On Track, CEO Says

Biomet says recent management and infrastructure changes to its struggling spine division will allow the business to begin growing again by mid-2009

Biomet’s Struggling Spine Business Is Nearly Back On Track, CEO Says

Biomet says recent management and infrastructure changes to its struggling spine division will allow the business to begin growing again by mid-2009

Biomet Plans No Major Restructuring Following Private Equity Buy-Out

Biomet's new CEO Jeffrey Binder said in an interview that he plans to maintain the company's current structure for the foreseeable future

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel